You just read:

BerGenBio Presents Preliminary Phase II Clinical Data at EHA 24: Bemcentinib in Combination With Low Dose Chemotherapy Yields Durable Responses in AML Patients Unfit for Intensive Chemotherapy

News provided by

BerGenBio ASA

14 Jun, 2019, 11:40 BST